Activest Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-365
Closed -$21.1K – 336
2022
Q4
$21.1K Hold
365
– – 0.01% 256
2022
Q3
$17K Buy
+365
New +$19.5K 0.01% 269

Other funds holding BIB

Activest Wealth Management's BIB Position: Q1 2023 in Review

Activest Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2023, closing a stake of 365 shares — an estimated $21.1K sold.

Activest Wealth Management first reported a position in BIB in Q3 2022 and held it in 2 quarters. The position peaked at $21.1K in Q4 2022. 24 funds tracked by Wall St. Rank hold BIB as of Q1 2023.

  • Activest Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Activest Wealth Management sold 365 ProShares Ultra NASDAQ Biotechnology shares in Q1 2023, an estimated $21.1K.
  • Activest Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2022 and held it in 2 quarters.
  • Activest Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $21.1K in Q4 2022.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2023.

Based on Activest Wealth Management's 13F filing for Q1 2023, filed 18 Apr 2023.